Serious adverse events in academic critical care research

CMAJ. Canadian Medical Association Journal

Volumn 178, Issue 9, 2008, Pages 1181-1184

  Cook, Deborah ^a,b,g   Lauzier, François ^d   Rocha, Marcelo G ^e   Sayles, Mary Jane ^c   Finfer, Simon ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b Department of Medicine ^*  (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e Irmandade Santa Casa de Misericordia   (Brazil)

^f University of Sydney   (Australia)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; INSULIN;

ANAMNESIS; BLEEDING; CLINICAL RESEARCH; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG INDUCED DISEASE; GOOD CLINICAL PRACTICE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE; NOTE; OUTCOME ASSESSMENT; PATIENT SAFETY; PEER REVIEW; PROPHYLAXIS; SEPSIS; THROMBOSIS;

EID: 42549083861     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071366     Document Type: Note

References (16)

1. ICH harmonised tripartite guideline. Guideline for good clinical practice E6 (R1). Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use;1996 Jun 10. Available: www.ich.org/LOB/media/MEDIA482.pdf (accessed 2008 Jan 15).
2. Cook D, Moore-Cox A, Xavier D, et al. Randomized trials in vulnerable populations. Clin Trials 2008;5:61-9.
3. Angus DC, Birmingham MC, Balk R, et al. E4 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators JAMA 2000;283:1723-30.
4. Santiago LM, Debanne SM, Neuhauser D. Tracking adverse events in RCTs: lack of agreement among regulatory institutions. Qual Saf Health Care 2003;12:234-5.
5. Guidelines on the reporting of adverse drug reactions by drug sponsors. Woden (Australia): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Available: www.tga.gov.au/docs/html/adrguide. htm (accessed 2008 Jan 15).
6. Roberts I, Yates D, Sandercock P, et al; CRASH Trial Collaborators. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo controlled trial. Lancet 2004;364:1321-8.
7. Normoglycaemia in intensive care evaluation and survival using glucose algorithm regulation (NICE - SUGAR STUDY) [study registration record]. Bethesda (MD): National Institutes of Health, ClinicalTrials.gov; 2005. Available: www.clinicaltrials.gov/ct/show/NCT00220987 (accessed 2007 Aug 18).
8. Hudson LD, Milberg JA, Anardi D, et al. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;151:293-301.
9. Cook DJ, Walters SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998;129:433-40.
10. Arnold DM, Donahoe L, Clarke FJ, et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007;30:E93-102.
11. Douketis J, Cook D, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med. In press.
12. Cook DJ, Rocker G, Meade M, et al; PROTECT Investigators; Canadian Critical Care Trials Group. Prophylaxis of ThromboEmbolism in Critical Care Trials (PROTECT): a pilot study. J Crit Care 2005;20:364-72.
13. Cook D, Rocker G, Marshall J, et al; Level of Care Study Investigators; Canadian Critical Care Trials Group. Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit. N Engl J Med 2003;349:1123-32.
14. DeMets DL, Fost N, Powers M. An institutional review board dilemma: responsible for safety monitoring but not in control. Clin Trials 2006:3:142-8.
15. Ioannidis JPA, Evans SJW, Gotzsche PC, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8.
16. Luce JM, Cook DJ, Martin TR, et al; American Thoracic Society. The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations [published erratum in Am J Respir Crit Care Med 2005 ;172:787]. Am J Respir Crit Care Med 2004;170:1375-84.